Genor Biopharma, a China-based drug developer that is engaged in development of a number of biosimilars, has completed a phase 1 study of a proposed infliximab biosimilar, GB242, referencing Remicade.
Genor Biopharma, a China-based drug developer that is engaged in development of a number of biosimilars targeting oncology and inflammatory indications, has completed a phase 1 study of a proposed infliximab biosimilar, GB242, referencing Remicade. Results of the study were published in BioDrugs.
The investigators conducted the randomized, double-blind, parallel-controlled study in 48 healthy subjects in a single center. The volunteers were assigned to receive either the proposed biosimilar or the reference infliximab at a dose of 3 mg/kg. Blood samples were collected to assess pharmacokinetics (PK) and immunogenicity, and safety was assessed throughout the study.
PK similarity was concluded if the 90% CIs for the geometric mean ratios of the biosimilar and the reference for maximum concentration (Cmax), area under the concentration—time curve (AUC) from time zero to the last quantifiable concentration (AUCt), and AUC from time zero to infinity (AUC∞) fell within the prespecified bioequivalence margin of 80% to 125%.
The authors report that the mean serum concentration—time curves were similar between the biosimilar and reference, and the 90% CIs for the geometric mean ratios of the 2 products for Cmax, AUCt, and AUC∞ were contained within the 80% to 125% margin, and therefore the products demonstrated bioequivalence.
The proportion of volunteers who experienced treatment-emergent adverse events was similar between the groups, as were antidrug antibody profiles.
According to the authors, the study showed high PK similarity between the proposed biosimilar and its reference, and the drugs showed similar safety and immunogenicity.
According to Genor, the proposed biosimilar product has now moved to phase 3 development.
Among the other biosimilars being developed by the company are GB221, a proposed trastuzumab in phase 3 development; GB232, a proposed adalimumab in phase 1 development with partners; GB222, a proposed bevacizumab entering phase 3 development; and GB241, a proposed rituximab in phase 1 development with partners.
Reference
Zhang T, Chen G, Liu C, et al. A phase 1 study comparing the pharmacokinetics, safety, and immunogenicity of proposed biosimilar GB242 and reference infliximab in healthy subjects. BioDrugs. 2019;33(1):93-100. doi: 10.1007/s40259-018-0326-x.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: EMA Announces Readiness to Waive Comparative Efficacy Studies of Biosimilars
March 4th 2024Sarfaraz K. Niazi, PhD, takes a look at the European Medicines Agency's (EMA) announcement that it will investigate whether comparative efficacy tests should be needed for a biosimilar to receive regulatory approval.